Merck & Company (MRK) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Merck & Company (MRK)

124.03

+0.49 (0.40%)

as of Jul 13, 2026, 8:00:00 pm Market Open.

311 watching

Investor Insights

Jul 13, 2026, 12:00 am

This summary was created by AI, based on 22 opinions in the last 12 months.

Merck & Company (MRK) is regarded as a strong investment opportunity, primarily due to its robust drug pipeline and significant growth potential despite challenges with its blockbuster drug, Keytruda, which is set to go off-patent in 2028. Analysts highlight the company's anticipated increase in sales, particularly from Keytruda and other new drugs in development. While some concerns exist regarding market fluctuations and pricing clarity, a substantial number of experts maintain an optimistic outlook on the stock's performance. With a promising array of drugs poised for release by 2030 and solid financial metrics, including rising cash reserves and share buybacks, MRK is projected to see continued growth, making it a compelling choice for healthcare investors. Expert recommendations suggest a prudent approach to stop-loss levels and target price adjustments.

Consensus

Bullish

Valuation

Undervalued

Similar

Pfeizer, PFE

DON'T BUY

Prefers Pfizer which has been doing more things correctly.

HOLD

This is a sector that he has avoided as they have had three years of poor experience. In the last 3/4 months, pharmaceuticals have started to wake up. This will not be the fastest growing area and this one will plod along.

BUY

Big pharmas have had a really tough go. He can now see them coming back. A good selection for a conservative, patient investor.

DON'T BUY

Has a lot of lawsuits overhanging it. Would not own it at this point.

PAST TOP PICK

(A Top Pick Aug 29/05. Up 14%.) Loves this name. An absolute steal. Facing class action lawsuits. This is what a value manager wants. A great company with a ton of free cash flow, strong dividend, pristine balance sheet and everybody hates.

DON'T BUY

Too early, particularly if the US has a recession. If we get into a recession, it will be a consumer led recession, there’s going to be humongous pressures by consumers and seniors on drugs for some of the egregious profits they have been making.

DON'T BUY

Drug stars such as Pfizer (PFE-N) Merck (MRK-N), etc. are attractively valued but are clearly out of favour. They have great long term track records and are in strong financial positions, however, there is a lack of predictability regarding the science. Doesn't like the cash flow dynamics where they spend billions up front with no sure win ahead. Litigation risks.

BUY

Pays a 5.5% dividend. If you have good fundamentals plus a dividend yield, you should do OK.

DON'T BUY

Has a pretty decent pipeline of new products. Current dividend yield is very high. You have to be prepared to ride out the storm of litigations, but could come out nicely. Very risky.

TOP PICK

Up to their necks in litigation. They've lost $30 billion in market cap because an anti-inflammatory has been pulled off the shelf due to heart attack risks. Just lost a $230 million lawsuit which will be reversed on appeal. Only trading at 9 X earnings. Have a ton of cash and generate a ton of free cash flow. 5.5% dividend yield. Very cheap.

DON'T BUY

Pharmaceutical sector did very poorly over the last 2 years, but deceleration in revenue growth has slowed and profitability has started to improve. Look for the strongest perfoming stock in the sector. As Eli Lilly (LLY-N) is performing better, that would be the better of the 2, but would suggest you look at Sanofi-Aventis (SNY-N) which is close to new highs and Teva Pharmaceuticals (TEVA-Q) in generics.

BUY

Pharmaceutical stocks in the US have been absolutely decimated. Dirt cheap. Generates a ton of free cash flow.

BUY

An equally good stock as Pfizer (PFE-N) at these levels. 4.5% yield. Always have good products. Going through a difficult spell right now.

BUY

Great valuation and a good entry point.

DON'T BUY

Would prefer Pfizer (PFE-N) which has a far superior pipeline.

Showing 226 to 240 of 305 entries

Most Recent Experts

Jim Cramer - Mad Money

CNBC

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Dan Rohinton

iA Global Asset Management

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Jenny Harrington, CEO, Gilman Hill Asset Management

Gilman Hill Asset Management

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Merck & Company (MRK)